Q13133 (NR1H3_HUMAN) Homo sapiens (Human)

Oxysterols receptor LXR-alpha UniProtKBInterProSTRINGInteractive Modelling

447 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3); 4 identical sequences: Homo sapiens: F1D8N1; Pan troglodytes: K7AUZ1, A0A6D2XX46; Pan paniscus: A0A2R9BV37

Available Structures

7 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Crystal structure of LXRalpha in complex with tert-butyl benzoate analog, compound 32b Heteromer
Q15788;
204-447
4KQ;
Assess
Crystal structure of LXRalpha in complex with tert-butyl benzoate analog, compound 4 Heteromer
Q15788;
204-446
4KM;
Assess
Identification of LXRbeta selective agonists for the treatment of Alzheimer's Disease Heteromer
Q15788;
205-446
668;SO4;
Assess
X-ray structure of benzisoxazole synthetic agonist bound to the LXR-alpha Heteromer
Q15788;
205-446
SO4;O90;
Assess
X-ray structure of benzisoxazole urea synthetic agonist bound to the LXR-alpha Heteromer
Q15788;
204-445
O40;SO4;
Assess
X-ray structure of GW3965 synthetic agonist bound to the LXR-alpha Heteromer
Q15788;
205-445
965;SO4;
Assess
Crystal structure of the LXRalfa-RXRbeta LBD heterodimer Heteromer
P28702; Q15596;
207-445
MEI;444;
Assess

12 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
4nqa.1.Bmonomer0.7485-444
ZN;73.70
Assess
4nqa.2.Bmonomer0.7486-445
ZN;965;73.70
Assess
5uan.1.Bmonomer0.6597-444
ZN;34.23
Assess
7wnh.4.Amonomer0.6298-444
ZN;29.43
Assess
7wnh.2.Amonomer0.6197-443
ZN;29.43
Assess
3dzy.1.Bmonomer0.6195-445
ZN;28.65
Assess
4iqr.2.Bmonomer0.5796-444
ZN;30.72
Assess
4iqr.2.Amonomer0.5796-444
ZN;30.72
Assess
7prw.1.Bmonomer0.5795-446
ZN;24.25
Assess
3dzy.1.Amonomer0.5295-430
ZN;31.09
Assess
5uan.1.Amonomer0.5297-430
ZN;31.49
Assess
4nqa.2.Amonomer0.5197-430
ZN;31.49
Assess

23 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 24nqa.1.Bmonomer0.6785-384
ZN;68.65
Assess
Isoform 24nqa.2.Bmonomer0.6586-385
ZN;68.65
Assess
Isoform 25uan.1.Bmonomer0.6397-384
ZN;30.82
Assess
Isoform 27wnh.2.Amonomer0.5897-383
ZN;27.68
Assess
Isoform 24iqr.1.Bmonomer0.5896-384
ZN;28.87
Assess
Isoform 24iqr.2.Amonomer0.5796-384
ZN;28.87
Assess
Isoform 23dzy.1.Amonomer0.5795-383
ZN;26.96
Assess
Isoform 23dzy.1.Bmonomer0.5695-385
ZN;28.37
Assess
Isoform 27wnh.4.Amonomer0.5698-384
ZN;27.68
Assess
Isoform 27prv.1.Bmonomer0.5495-386
ZN;22.68
Assess
Isoform 27prw.1.Amonomer0.5495-386
ZN;22.68
Assess
Isoform 34nqa.1.Bmonomer0.7540-399
ZN;73.70
Assess
Isoform 34nqa.2.Bmonomer0.7441-400
ZN;965;74.38
Assess
Isoform 35uan.1.Bmonomer0.6652-399
ZN;34.23
Assess
Isoform 37wnh.4.Amonomer0.6253-400
ZN;29.04
Assess
Isoform 37wnh.2.Amonomer0.6252-398
ZN;29.04
Assess
Isoform 33dzy.1.Bmonomer0.6150-399
ZN;28.94
Assess
Isoform 34iqr.2.Bmonomer0.5951-399
ZN;31.03
Assess
Isoform 34iqr.2.Amonomer0.5851-399
ZN;31.03
Assess
Isoform 37prv.1.Bmonomer0.5850-401
ZN;24.25
Assess
Isoform 33dzy.1.Amonomer0.5450-385
ZN;30.25
Assess
Isoform 35uan.1.Amonomer0.5352-385
ZN;31.49
Assess
Isoform 34nqa.2.Amonomer0.5152-385
ZN;31.49
Assess